skip to main content
TFRI_PMCF_Banner_2204_V2-01

This one-day symposium in Toronto will feature talks from investigators funded through the Marathon of Hope Cancer Centres Network (MOHCCN) and the Terry Fox Research Institute. Presenters will be researchers from the MOHCCN projects and TFRI Program Project Grants based in Ontario.

The Terry Fox Research Institute and Princess Margaret Cancer Centre Joint Symposium
Attendance in person and virtually. In person attendance is limited.

Thursday July 7, 2022

8:00 am - 4 pm EST

Keynote Speaker: Dr. Charles Swanton, The Francis Crick Institute, UK, presenting:
“TRACERx: Insights into Primary Metastatic Lung Cancer Evolution"

Deadline to Register: June 15, 2022

Register Now


Important information for on site attendees:

Venue:
Princess Margaret Cancer Centre, Auditorium (6th floor)
610 University Avenue, Toronto, Ontario, M5G 1Z5

Box lunch provided.

Reception to follow at Princess Margaret Cancer Foundation

Agenda

TFRI_PMCF_Banner_2204_V2-01

Joint Terry Fox Research Institute and Princess Margaret Cancer Centre Symposium

Date: Thursday July 7, 2022
Time: 8 am - 4 pm EST
Format: Hybrid (in-person and virtual)
Venue: Princess Margaret Cancer Centre, Auditorium (6th floor)
             610 University Avenue, Toronto, Ontario, M5G 1Z5

Co-sponsors:
Terry Fox Research Institute, Princess Margaret Cancer Centre/Princess Margaret Cancer Foundation

Time

Topic

Speaker

8:00-8:15 am

Opening Remarks

Jim Woodgett, TFRI President and Scientific Director

Darrell Fox, TFRI Senior Advisor

Brad Wouters, Executive Vice-President, Science and Research, University Health Network

 

Introduction of Keynote Speaker

Jim Woodgett

8:15-9:00 am

Keynote Speaker (virtual presentation)

“TRACERx: Insights into Primary Metastatic Lung Cancer Evolution”

Charles Swanton, The Francis Crick Institute, UK

 

Moderator of PPG Sessions

Jim Woodgett

9:00-10:30 am

(20 min presentation, 10 min Q&A each)

“Heterogeneous Patterns of Hypoxia Shaping the Tumour Microenvironment”

 

Marianne Koritzinsky, Scientist, PMCC and Associate Professor and Director of Research, Radiation Oncology, University of Toronto/Gelareh Zadeh, Neurosurgeon-Scientist, Toronto Western Hospital, UHN and Professor, Surgery, University of Toronto

“Multifunctional Nanoparticles for Cancer Theranostics: Towards First Clinical Trials”

Brian C. Wilson

Senior Scientist, Princess Margaret Cancer Centre,

Professor of Medical Biophysics, University of Toronto/Sharon Tzelnick, Clinical Fellow, Otolaryngology - Head and Neck Surgery, University of Toronto

“Using in vivo CRISPR tools to systematically delineate breast cancer driver genes”

 

Daniel Schramek, Senior scientist Lunenfeld Tannenbaum Research Institute, Associate professor, Department of Molecular Genetics, Temertry Faculty of Medicine, UofT Canadian research chair in functional cancer genomics 

10:30-11:00 a

Break

 

 

11:00-12:00 pm

(20 min presentation, 10 min Q&A each)

“Synthetic Virology Strategies to Create Cancer Therapeutics”

 

Taha Azad, Researcher, Ottawa Hospital Research Institute and Biomedical and Molecular Science, Queen’s University

“Is Cancer a Wound that Keeps on Healing? A New Perspective on Glioblastoma”

Peter Dirks, Professor, Molecular Genetics, University of Toronto; Senior Scientist, Developmental Biology, The Hospital for Sick ChildrenResearch Institute; and Chief of Neurosurgery, The Hospital for Sick Children

 

 

12:00-1:00 pm

Lunch

 

1:00-1:30 pm

Princess Margaret Cancer Consortium (MOHCCN) presentation

Trevor Pugh, Senior Investigator and Director of Genomics, OICR, and Senior Scientist, Princess Margaret Cancer Centre

Mike Brudno, Professor, Computer Science, University of Toronto and Chief Data Scientist, University Health Network

Lillian Siu, Senior Medical Oncologist, Princess Margaret Cancer Centre and Professor, Medicine, University of Toronto

1:30-2:00 pm

PROFYLE

David Malkin, Director, Cancer Genetics Program and Senior Scientist, Sick Kids and Professor, Pediatrics, University of Toronto

2:00-2:42 pm

Fireside Chat: “What is the Next Frontier to Battle Cancer?”

Moderated by Aaron Schimmer, Senior Scientist, Princess Margaret Cancer Centre (PMCC) and Director, Research Institute, PMCC

Panelists:

Cheryl Arrowsmith, Senior Scientist, Ontario Cancer Institute/Princess Margaret Cancer, and Professor, Medical Biophysics, U of T(TBC)

Philippe Bedard, Staff Medical Oncologist and Clinical Director, Genomics Program, Princess Margaret Cancer Centre

Sheila Singh, Professor, Surgery and Biochemistry, and Director, Pediatric Brain Tumour Study Group, Faculty of Health Sciences, McMaster University

Uri Tabori, Senior Scientist, SickKids and Professor, Pediatrics, University of Toronto and

Christine Williams, Immunologist and Executive Vice-President and Head, Implementation Science, Ontario Institute for Cancer Research

 

2:43- 2:45 pm

Closing Remarks

André Veillette, Executive Director, MOHCCN and Director, Molecular Oncology Research Unit, IRCM and Professor of Medicine, Université de Montréal

Walk to Reception

3:00-4:00 pm

Reception at the Princess Margaret Cancer Foundation (700 University Avenue, 4th floor)

 


TFRI_PMCF_Banner_2204_V2-01
Swanton_Charles

Professor Charles Swanton MBPhD, FRCP, FMedSci, FAACR, FRS

Keynote Talk: “TRACERx: Insights into Primary Metastatic Lung Cancer Evolution”

Charles completed his MBPhD training in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. He is a senior group leader of the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute and combines his research with clinical duties at UCLH, as a thoracic oncologist, focussed on how tumours evolve over space and time. His research branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome. Charles is chief investigator of TRACERx, a lung cancer evolutionary study and the national PEACE autopsy program.

 Charles was made Fellow of the Royal College of Physicians in April 2011, appointed Fellow of the Academy of Medical Sciences in 2015, awarded the Napier Professorship in Cancer by the Royal Society in 2016, appointed Cancer Research UK’s Chief Clinician in 2017, elected Fellow of the Royal Society in 2018, and Fellow of the Academy of the American Association for Cancer Research in 2020. He is an editorial board member of Cell, Plos Medicine, Cancer Discovery and Annals of Oncology and an advisory board member for Nature Reviews Clinical Oncology and Cancer Cell. In 2016 he co-founded Achilles Therapeutics, a UCL/CRUK/Francis Crick Institute spin-out company, assessing the efficacy of T cells targeting clonal neoantigens. 

 Charles has been awarded several prizes including the Stand up to Cancer Translational Cancer Research Prize (2015), GlaxoSmithkline Biochemical Society Prize (2016), San Salvatore prize for Cancer Research (2017) and the Ellison-Cliffe Medal, Royal Society of Medicine (2017), recipient of the Gordon Hamilton Fairley Medal (2018), Massachusetts General Hospital, Jonathan Kraft Prize for Excellence in Cancer Research (May 2018), the ESMO Award for Translational Cancer Research (2019), Addario Lung Cancer Foundation Award and Lectureship, International Lung Cancer Congress (July 2020), the Weizmann Institute Sergio Lombroso Award in Cancer Research (2021), International Society of Liquid Biopsy (ISLB) Research Award (2021), and the Memorial Sloan Kettering Paul Marks Prize for Cancer Research (2021).

TFRI_PMCF_Banner_2204_V2-01

Contact Us

For any questions on this symposium, please contact:

Kelly Curwin
Chief Communications Officer
Terry Fox Research Institute
kcurwin@tfri.ca

Sevan Hakgor
MOHCCN Project Manager for the PM2C
Princess Margaret Cacer Centre
MOHCCN@uhn.ca